{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:13:06Z","timestamp":1787166786523,"version":"build-2736575974"},"reference-count":20,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mem. Inst. Oswaldo Cruz"],"DOI":"10.1590\/0074-02760180420","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T13:28:02Z","timestamp":1549718882000},"source":"Crossref","is-referenced-by-count":4,"title":["Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?"],"prefix":"10.1590","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8743-2986","authenticated-orcid":false,"given":"Carolina Arana Stanis","family":"Schmaltz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda de Oliveira","family":"Demitto","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Marinho","family":"Sant\u2019Anna","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Cavalcanti","family":"Rolla","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2019]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3851\/IMP1455","article-title":"Effectiveness and safety of antiretrovirals with rifampicin crucial issues for high-burden countries","volume":"14","author":"Maartens G","year":"2009","journal-title":"Antivir Ther"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/civ477","article-title":"Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy","volume":"61","author":"Taburet A-M","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032173","article-title":"The safety, effectiveness and concentrations of adjusted lopinavir\/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy","volume":"7","author":"Decloedt EH","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1128\/AAC.00461-06","article-title":"Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers","volume":"50","author":"Burger DM","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","article-title":"Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections focus on drug-drug interactions with rifamycins","volume":"53","author":"Regazzi M","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAD.0b013e32835a67fb","article-title":"No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients","volume":"27","author":"Singh R","year":"2013","journal-title":"AIDS"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5588\/ijtld.10.0626","article-title":"Protease inhibitor-containing antiretroviral treatment and tuberculosis can rifabutin fill the breach?","volume":"16","author":"Loeliger A","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref8","first-page":"288 pp","year":"2011"},{"key":"ref9","first-page":"3 pp","article-title":"Nota t\u00e9cnica sobre as mudan\u00e7as no tratamento da tuberculose no Brasil para adultos e adolescentes","year":"2009","journal-title":"Vers\u00e3o 2"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/QAI.0000000000000944","article-title":"Critical review what dose of rifabutin is recommended with antiretroviral therapy?","volume":"72","author":"Yapa HM","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1164\/rccm.200503-417OC","article-title":"Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis","volume":"173","author":"Burman W","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.5588\/ijtld.15.0997","article-title":"Improved tuberculosis outcomes with daily vs intermittent rifabutin in HIV-TB coinfected patients in India","volume":"20","author":"Jenks JD","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/QAI.0b013e3181b31e56","article-title":"Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil","volume":"52","author":"Schmaltz CAS","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref14","first-page":"7 pp","article-title":"Pharmacological interaction of lopinavir\/ritonavir 800\/200 mg BID and rifampicin in subjects presenting tuberculosis with contraindication for an efavirenz containing antiretroviral regimen","author":"Schmaltz CAS","year":"2014","journal-title":"J AIDS Clin Res"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/QAI.0000000000000515","article-title":"Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy","volume":"68","author":"Rawson TM","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-157-5-201209040-00004","article-title":"The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis findings from the SAPiT trial","volume":"157","author":"Naidoo K","year":"2012","journal-title":"Ann Intern Med"},{"issue":"16","key":"ref17","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1097\/01.aids.0000432456.14099.c7","article-title":"Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial","volume":"27","author":"Laureillard D","year":"2013","journal-title":"AIDS"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1590\/S1413-86702007000500004","article-title":"Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro","volume":"11","author":"Serra FC","year":"2007","journal-title":"Braz J Infect Dis"},{"key":"ref19","first-page":"23 pp","article-title":"Rifabutin for treating pulmonary tuberculosis","author":"Davies GR","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkt446","article-title":"Safety of rifabutin replacing rifampicin in the treatment of tuberculosis a single-centre retrospective cohort study","volume":"69","author":"Chien J-Y","year":"2014","journal-title":"J Antimicrob Chemother"}],"container-title":["Mem\u00f3rias do Instituto Oswaldo Cruz"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/mioc\/v114\/1678-8060-mioc-114-e180420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T13:35:42Z","timestamp":1579872942000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0074-02762019000100312&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":20,"alternative-id":["S0074-02762019000100312"],"URL":"https:\/\/doi.org\/10.1590\/0074-02760180420","relation":{},"ISSN":["1678-8060","0074-0276"],"issn-type":[{"value":"1678-8060","type":"electronic"},{"value":"0074-0276","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"article-number":"e180420"}}